Aquestive Therapeutics, Inc. (AQST) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Aquestive Therapeutics is a pharmaceutical company focused on developing medicines delivered via alternative administration methods (e.g., oral films). Key business developments in the period include the April 2024 FDA approval and launch of Libervant (diazepam buccal film) for pediatric epilepsy (ages 2-5) and the advancement of the Anaphylm (epinephrine sublingual film) program toward an expected NDA submission in late 2024/early 2025. The company operates as a smaller reporting company and is the exclusive manufacturer for several licensed products, including Suboxone.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | Value (in thousands) |
|---|---|
| Total Revenues | $32,152 |
| Net Loss | $(15,573) |
| Operating Loss | $(8,902) |
| Cash and Cash Equivalents (as of June 30, 2024) | $89,870 |
| Net Cash Used in Operating Activities | $(17,390) |
| Net Cash Provided by Financing Activities | $83,452 |
| Total Debt (Notes Payable, net) | $30,006 |
| Royalty Obligations (net) | $17,477 |
| Stockholders' Deficit | $(35,479) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 32% year-over-year (YoY) to $32.15 million for the six months ended June 30, 2024, compared to $24.38 million in 2023. This was driven primarily by a 415% increase in license and royalty revenue due to one-time recognitions from terminated agreements (Haisco and MTPA).
- Manufacture and Supply: Revenue from manufacture and supply decreased 13% YoY to $18.64 million, attributed to lower volumes of Ondif and Suboxone.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 49% YoY to $22.05 million, driven by higher personnel costs, share-based compensation, and regulatory fees for Libervant. Research and development (R&D) expenses increased 44% YoY to $10.09 million, primarily due to clinical trial costs for Anaphylm.
- Interest Expense: Interest expense nearly doubled (98% increase) to $5.56 million, largely due to the amortization of debt issuance costs and discounts associated with the 13.5% Senior Secured Notes issued in November 2023.
- Liquidity Position: Cash balances increased significantly from $23.87 million at year-end 2023 to $89.87 million at June 30, 2024, following a $72.9 million underwritten public offering and ATM sales.
Guidance, Outlook, and Risks
- Product Pipeline: Management expects to file the NDA for Anaphylm in December 2024, with a potential launch in late 2025 or early 2026. Libervant commercialization is underway for the 2-5 age group, with plans to expand sales representation and distribution.
- Liquidity Outlook: Management states that existing cash, expense management, and access to equity markets (ATM facility) provide sufficient liquidity to fund operations for at least the next 12 months.
- Debt Obligations: The company carries $45 million in 13.5% Senior Secured Notes due 2028. Principal payments on these notes begin in June 2026. There are also royalty obligations tied to future sales of Anaphylm and Libervant.
- Legal Contingencies: Significant risks include ongoing Suboxone product liability litigation (over 560 lawsuits consolidated in MDL), patent litigation, and a lawsuit by Neurelis challenging the FDA approval of Libervant for pediatric patients.
- Revenue Volatility: Future revenues remain heavily dependent on the Suboxone franchise, which faces generic competition, and the successful commercialization of new products.
Key Facts for Investor Verification
- Contract Terminations: Verify the impact of the terminated agreements with Haisco and MTPA, which resulted in one-time revenue recognition of approximately $10.3 million but eliminated future royalty and manufacturing streams from these partners.
- Debt Service Capacity: Assess the company's ability to service the 13.5% Notes (interest-only until 2026, then amortizing) and meet royalty obligations given the current burn rate and reliance on future product launches.
- Libervant Market Access: Monitor the outcome of the Neurelis lawsuit challenging Libervant's approval and the timeline for overcoming orphan drug exclusivity to access the 6+ age group (currently blocked until Jan 2027).
- Anaphylm Regulatory Path: Track the progress of the ongoing clinical studies and the scheduled pre-NDA meeting with the FDA in late 2024.
- Suboxone Volume Trends: Monitor quarterly Suboxone manufacturing volumes to gauge the erosion of market share to generic competitors.